Health Care · Retail-Drug Stores and Proprietary Stores

CVS CVS Health SEC Filings & Insider Trading Activity 2026

company
CIK 6480391 filings
S&P 500

CVS at a glance

CVS Health (CVS, SEC CIK 64803) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CVS Health (CVS) reported revenue of $402.1 billion (up 7.8% from FY2024) and net income of $1.8 billion. Diluted EPS was $1.39.
  • As of September 30, 2026, 56 institutional investment managers tracked by SignalX reported holding CVS Health (CVS) shares worth $41.3 billion in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Shah Prem S on November 6, 2026 of 23,855 shares at $83.89 per share.
  • In the last 90 days, CVS insiders reported 1 open-market purchase ($2.0M) and 0 open-market sales ($0) on Form 4, a net purchase of $2.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$402.1B
+7.8% vs prior year
Insiders · 90 days
1 buy · 0 sells
Net +$2.0M
13F holders
56 funds
$41.3B · −5 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business risk focus on compliance with extensive laws, regulations, and contractual requirements in healthcare sectors
  • Increased litigation exposure due to vertical integration strategy and expanded healthcare services
  • Ongoing costly class action, qui tam, securities, and derivative litigation with potential high damages, not fully insured
  • Heightened regulatory audits, inspections, government inquiries, and legal proceedings inside and outside U.S.
  • Insurance coverage limits highlighted with risks of unavailable or insufficient insurance, especially for punitive damages

Risk Factors

  • Opioid litigation risk: $320 million accrual increase for ongoing opioid litigation matters in 2025
  • Geopolitical/macroeconomic exposure: Medicare Advantage segment served 37 million people, sensitive to CMS policy changes
  • Supply chain vulnerability: Reliance on pharmaceutical pricing negotiations through group purchasing organization for drug cost management
  • Competitive risk: Health Services segment faces disruption from Signify Health and Oak Street Health in value-based primary care
  • Financial risk: $5.7 billion goodwill impairment in Health Care Delivery reporting unit in 2025 impacting operating income

Management Discussion & Analysis

  • Market valuation risk: $3.6B fair value decline in long-term debt with 100bp rate increase; no impact on operations
  • Interest rate sensitive investment net fair value decline approx. $765M, recorded as unrealized loss in equity
  • No material foreign currency or commodity derivative exposures as of Dec 31, 2025
  • Cybersecurity risks ongoing; no material impact on operations; significant resources allocated to risk mitigation

AI summary of the CVS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added separation risk triggered by November 4, 2026 announcement to create CVS Health and CVS Pharmacy
  • Operational risk: management distraction from separation could disrupt ongoing business and adversely affect results
  • Regulatory and tax risk: separation requires SEC Form 10 effectiveness and confirmation of tax-free treatment
  • Execution risk: separation expected first half of 2028, subject to Board approval and independent-company readiness
  • Financial risk: dis-synergy, restructuring and transaction costs could exceed estimates

Management Discussion & Analysis

  • Revenue $108.4B, up 5.4% YoY from $102.9B, driven by Health Services and Health Care Benefits
  • Operating margin 3.3% vs (3.1)% YoY, with operating income $3.6B vs $3.2B loss
  • Best segment Health Services: revenue $54.0B, up 9.5%; adjusted operating margin 3.9% vs 4.2%
  • Worst segment Pharmacy & Consumer Wellness: revenue $35.5B, down 2.0%; adjusted operating margin 4.6% vs 4.1%
  • Cash $11.7B; nine-month operating cash flow $15.3B, up $8.1B, with $5.5B investing outflows and no share repurchases
  • Outlook headwinds: elevated utilization, PBM pricing pressure, regulatory changes, inflation, tariffs and weaker discretionary spending

AI summary of the CVS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Planned tax-free separation by first half 2028 into CVS Health healthcare solutions and CVS Pharmacy retail operations
  • CVS Health to include Aetna, Caremark, Specialty, Oak Street Health and Signify Health

Item 7.01: Regulation FD Disclosure

  • CVS intends to separate into two independent, publicly traded companies
  • Transaction structured to be tax-free for CVS and shareholders under U.S. federal income tax rules
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • CVS Health reported results for the three months ended September 30, 2026
  • Press release issued November 4, 2026, with financial details in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $108.4B, up 5.4% YoY, with adjusted operating income rising 21.2% to $4.2B
  • Adjusted EPS $2.09, up from $1.60, driven primarily by Health Care Benefits margin recovery
Filed Aug 17, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Larry M. Robbins resigned from CVS Health’s Board effective August 13, 2026
  • Resignation unrelated to disagreements over company operations, policies, or practices

Item EX-99.1: Item EX-99.1

  • Teresa Heitsenrether joins CVS’s Board effective November 18, 2026, adding data, analytics, AI and technology-transformation expertise
  • Heitsenrether’s JPMorgan operating background supports CVS’s stated strategy to become a consumer-focused health technology company

Item 7.01: Regulation FD Disclosure

  • Board appointment of Ms. Heitsenrether, adding a new director to CVS Health’s oversight structure
  • Mr. Robbins’s board resignation, reducing the current director roster and potentially changing board dynamics

AI summaries of CVS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CVS

Don't miss the next CVS filing

  • Alerts as it files. A push when CVS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CVS, by share count.
  • Ask anything. An AI agent that reads every CVS filing and answers with sources.

CVS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Shah Prem SBuyNov 6, 2026$83.89
Clark James DavidFJun 26, 2026$90.98
Newman BrianFMay 31, 2026$90.98
Compton-Phillips AmyFMay 31, 2026$90.98
Shulman Douglas H.AMay 14, 2026$97.15
Norwalk Leslie VAMay 14, 2026$97.15
Clark James DavidFApr 1, 2026$72.49
Shah Prem SFApr 1, 2026$72.49

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$372.8B$402.1B
Operating Income-$8.5B$4.7B
Net Income$8.3B$4.6B$1.8B
Op. Margin-2.3%1.2%
Net Margin-1.2%0.4%
Balance Sheet
Total Assets-$253.2B$253.5B
Equity$76.5B$75.6B$75.2B
ROE10.9%6.1%2.4%
Per Share
EPS$6.47$3.66$1.39
Cash Flow
Operating CF-$9.1B$10.6B
CapEx$3.0B$2.8B$2.8B

Source: XBRL data in CVS Health (CVS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CVS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CVS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202656$41.35B
Q2 202661$54.06B
Q1 202655$37.08B
Q4 202554$42.19B
Q3 202559$43.97B
Q2 202554$37.42B
Q1 202555$25.74B
Q4 202450$13.89B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 444 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CVS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 6, 2026--
13F-HRNov 5, 2026-
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KNov 4, 2026Analysis-
8-KAug 17, 2026Analysis-
13F-HRAug 6, 2026-
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Jun 29, 2026--
4Jun 1, 2026-
4Jun 1, 2026-
8-KMay 18, 2026Analysis
4May 15, 2026-
4May 15, 2026-
13F-HRMay 7, 2026-
10-QMay 6, 2026Analysis
8-KMay 6, 2026Analysis
SC 13GApr 29, 2026-
4Apr 2, 2026--
4Apr 2, 2026--
4Apr 2, 2026--
4Apr 2, 2026--
4Apr 2, 2026--
4Apr 2, 2026--

Related Health Care companies

All Health Care →

CVS SEC filings: frequently asked questions

Are CVS insiders buying or selling?

In the last 90 days, CVS Health (CVS) officers, directors and 10% owners reported 1 open-market purchase worth $2.0 million by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CVS stock?

As of September 30, 2026, the largest CVS Health (CVS) holders among the 13F filers tracked by SignalX were BlackRock ($10.3 billion), Vanguard Capital Management LLC ($7.2 billion), State Street Corp ($5.1 billion), Vanguard Portfolio Management LLC ($2.3 billion), Bank of America Corp ($2.0 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CVS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CVS Health (CVS) reported revenue of $402.1 billion (up 7.8% from FY2024) and net income of $1.8 billion. Diluted EPS was $1.39. The figures come from the XBRL data in the 10-K.

What are the main risks in CVS's latest 10-K?

In the 10-K filed February 10, 2026, CVS Health (CVS) flagged: Opioid litigation risk: $320 million accrual increase for ongoing opioid litigation matters in 2025. Geopolitical/macroeconomic exposure: Medicare Advantage segment served 37 million people, sensitive to CMS policy changes. (AI summary of the Risk Factors section.)

What did CVS report in its latest 8-K?

CVS Health (CVS) filed an 8-K on November 4, 2026 reporting Item 7.01 (Regulation FD Disclosure). Planned tax-free separation by first half 2028 into CVS Health healthcare solutions and CVS Pharmacy retail operations.

What are the latest CVS SEC filings?

CVS Health (CVS) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 6, 2026.

What is CVS's SEC CIK number?

CVS Health (CVS)'s SEC Central Index Key (CIK) is 64803. EDGAR lists every CVS filing under that number.

Ask anything about CVS

The research agent reads CVS's filings, financials, insider trades and 13F holders, then answers with sources.